Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 22, Number 3—March 2016

Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Table 1

World Health Organization recommendations for the programmatic use of bedaquiline and delamanid to treat multidrug-resistant tuberculosis

Recommendation
1. The drug is used under carefully monitored conditions.
2. Patients to receive the drug are carefully selected.
3. The drug is used as part of a World Health Organization–recommended treatment regimen.
4. Patients to receive the drug sign an informed consent; for delamanid, the recommendation is only for “due process” for informed consent.
5. Adverse events, including active pharmacovigilance, are actively managed.

Main Article

TOP